Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Apply
Dato-DXd vs. Docetaxel
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step